← Search & browse all drugs
NERVOUS SYSTEM › PSYCHOANALEPTICS › ANTIDEPRESSANTS › Other antidepressants
reboxetine
N06AX18
Adult Dosing
- Initial: 4 mg orally twice daily (morning and evening)
- Maximum: 10 mg/daily
- Titration: May increase to 8 mg/daily after 3-4 weeks if well-tolerated
Pediatric Dosing
- Not recommended for use in children and adolescents under 18 years of age due to lack of efficacy and safety concerns
Indications
- Treatment of major depressive episodes (authorized in select European and international markets, not FDA-approved in the US)
Mechanism of Action
- Selective norepinephrine reuptake inhibitor (NaRI)
- Enhances noradrenergic neurotransmission in the central nervous system by blocking the norepinephrine transporter
Contraindications
- Hypersensitivity to reboxetine
- Concurrent use with monoamine oxidase inhibitors (MAOIs)
- Severe cardiac disease
- Narrow-angle glaucoma
Adverse Reactions
- Insomnia
- Dizziness
- Dry mouth
- Constipation
- Nausea
- Tachycardia
- Urinary hesitancy or retention
- Excessive sweating
- Erectile dysfunction
Drug Interactions
- MAOIs: risk of hypertensive crisis and serotonin syndrome-like effects
- CYP3A4 inhibitors (e.g., ketoconazole, erythromycin): may increase reboxetine plasma concentrations
- Antihypertensive agents: potential for enhanced blood pressure lowering effects
- Potassium-depleting diuretics: increased risk of hypokalemia
Curated Content: Needs Vetting Before Put to Clinical Use